2016-003367-19: A study to compare norursodeoxycholic acid with placebo in the treatment of primary sclerosing cholangitis |
|
|
| Ongoing | 3 | 300 | Europe, RoW | Norursodeoxycholic acid, [NorUDCA], Capsule | Dr. Falk Pharma GmbH, DR. FALK PHARMA GMBH, Dr. Falk Pharma GmbH, | Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of assumed autoimmune, but finally unidentified etiology, characterized by a chronic inflammatory and fibro-obliterative destruction of extra-, and intrahepatic bile ducts. The disease is characterized by diffuse inflammation, fibrosis, and strictures of the intra- and/or extrahepatic bile ducts with an impaired biliary secretion of potentially aggressive bile fluid often leading to cirrhosis., Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic liver disease characterized by changes in the gall ducts inside and/or outside the liver, such as narrowing or enlargement., Diseases [C] - Digestive System Diseases [C06] | | | | |
| Active, not recruiting | 3 | 303 | Europe | norUrsodeoxycholic Acid, NUC | Dr. Falk Pharma GmbH | Primary Sclerosing Cholangitis | 01/25 | 06/26 | | |
2013-004605-38: Clinical trial comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of non-alcoholic fatty liver disease Klinische Studie welche zwei verschiedene Konzentrationen von Norursodeoxycholsäure Kapseln mit Placebo in der Behandlung der nicht alkoholischen Fettleber vergleicht |
|
|
| Ongoing | 2 | 156 | Europe | Norursodeoxycholic acid, norUDCA, | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | Non-alcoholic fatty liver disease (NAFLD) | | | | |
| Recruiting | 2 | 363 | Europe | norUrsodeoxycholic acid, norucholic acid, norUDCA, NCA | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH, | Nonalcoholic Steatohepatitis | 01/25 | 04/25 | | |
